At a glance
ClinicalIndex Comparison Record- ✓Locally advanced or metastatic non-small cell lung cancer
- ✓No more than 2 prior chemotherapy regimens, including a platinum-based regimen
- ✕Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitors, or other angiogenic inhibitors
- ✕History of or known brain metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating erlotinib, sunitinib, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 162 participants across 32 sites in 8 countries.
Detailed Summary
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
Study Details
Timeline
Interventions
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity